ConductScience.org, home

Paper36978917

Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers.

Freire Boullosa L and 11 others. Antioxidants (Basel), 2023. Cited by 20 papers, by iCite.

Cite this record

ConductScience Library. Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers. Papers, record 36978917. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36978917

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers.
PubMed
Journal
Antioxidants (Basel)
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
20
iCite
Relative citation ratio, by iCite
2.17
iCite
Revised in PubMed
2023-03-31
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Freire Boullosa LLauriehttps://orcid.org/0000-0001-6788-6211
2Van Loenhout JJinthehttps://orcid.org/0000-0001-8576-5640
3Flieswasser TTal
4Hermans CChristophe
5Merlin CCéline
6Lau HWHo Wa
7Marcq EEllyhttps://orcid.org/0000-0003-3173-0500
8Verschuuren MMarlieshttps://orcid.org/0000-0003-0357-7422
9De Vos WHWinnok Hhttps://orcid.org/0000-0003-0960-6781
10Lardon FFiliphttps://orcid.org/0000-0001-7174-4144
11Smits ELJEvelien L Jhttps://orcid.org/0000-0001-9255-3435
12Deben CChristophehttps://orcid.org/0000-0001-8085-2040

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
11E7719 NResearch Foundation - FlandersPubMed
1520819 NResearch Foundation - FlandersPubMed
NCR 19-20366AstraZeneca (France)PubMed

Source PubMed

Download CSV of grants

References74

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129416738PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation.Oncotarget2018https://conductscience.org/library/papers/29416738PubMed
230645701Pancreatic cancer microenvironment: a current dilemma.Clin Transl Med2019https://conductscience.org/library/papers/30645701PubMed
328452926KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer.Cancers (Basel)2017https://conductscience.org/library/papers/28452926PubMed
426776881Auranofin-loaded nanoparticles as a new therapeutic tool to fight streptococcal infections.Sci Rep2016https://conductscience.org/library/papers/26776881PubMed
529577855Nanoparticles in Cancer Treatment: Opportunities and Obstacles.Curr Drug Targets2018https://conductscience.org/library/papers/29577855PubMed
624157875APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase.Cell Death Dis2013https://conductscience.org/library/papers/24157875PubMed
721779443The genomics of lung adenocarcinoma: opportunities for targeted therapies.Genes Cancer2010https://conductscience.org/library/papers/21779443PubMed
826431378Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancer.Oncotarget2015https://conductscience.org/library/papers/26431378PubMed
933575569Omics Playground: a comprehensive self-service platform for visualization, analytics and exploration of Big Omics Data.NAR Genom Bioinform2020https://conductscience.org/library/papers/33575569PubMed
1035580060SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples.Nucleic Acids Res2022https://conductscience.org/library/papers/35580060PubMed
1127582430Excessive Reactive Oxygen Species and Exotic DNA Lesions as an Exploitable Liability.Biochemistry2016https://conductscience.org/library/papers/27582430PubMed
1232782491PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers.Ther Adv Med Oncol2020https://conductscience.org/library/papers/32782491PubMed
1334426760Reactive Oxygen Species (ROS) Regulates Different Types of Cell Death by Acting as a Rheostat.Oxid Med Cell Longev2021https://conductscience.org/library/papers/34426760PubMed
1422711857BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.J Clin Oncol2012https://conductscience.org/library/papers/22711857PubMed
1533088256Which concentrations are optimal for in vitro testing?EXCLI J2020https://conductscience.org/library/papers/33088256PubMed
1633837299Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin.Br J Cancer2021https://conductscience.org/library/papers/33837299PubMed
1724287781Modulation of oxidative stress as an anticancer strategy.Nat Rev Drug Discov2013https://conductscience.org/library/papers/24287781PubMed
1822899716Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species.J Cell Sci2012https://conductscience.org/library/papers/22899716PubMed
1926975633APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.Cancer Lett2016https://conductscience.org/library/papers/26975633PubMed
2035201489The gold complex auranofin: new perspectives for cancer therapy.Discov Oncol2021https://conductscience.org/library/papers/35201489PubMed

See all 74 referencesDownload CSV of references

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.

PMIDTitleJournalYearIn PapersSource
42529971TrxR Inhibition and Nrf2-FOXO3 Modulation by Repurposed Drugs: A Redox Strategy to Reverse Cancer Multidrug Resistance.Drug Dev Res2026https://conductscience.org/library/papers/42529971PubMed
41683548Auranofin Combination Therapy: A New Frontier in Cancer Treatment.Molecules2026https://conductscience.org/library/papers/41683548PubMed
41458252Spray Drying for Pharmaceutical Raw Materials: A Systematic Review on Enhancing Bioavailability and Stability.Drug Des Devel Ther2025https://conductscience.org/library/papers/41458252PubMed
41392982Auranofin attenuates TOPBP1-mediated ATR replication stress response and improves chemotherapeutic response in breast tumor models.J Clin Invest2025https://conductscience.org/library/papers/41392982PubMed
39288141Repurposing auranofin and meclofenamic acid as energy-metabolism inhibitors and anti-cancer drugs.PLoS One2024https://conductscience.org/library/papers/39288141PubMed
39187531NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced autophagy.Cell Death Dis2024https://conductscience.org/library/papers/39187531PubMed
39065655Investigation of Stabilized Amorphous Solid Dispersions to Improve Oral Olaparib Absorption.Pharmaceutics2024https://conductscience.org/library/papers/39065655PubMed
38590196[Role of Ferroptosis in Non-small Cell Lung Cancer and Progress of Traditional Chinese Medicine Intervention].Zhongguo Fei Ai Za Zhi2024https://conductscience.org/library/papers/38590196PubMed
38515565Ferroptosis in lung cancer: dual role, multi-level regulation, and new therapeutic strategies.Front Oncol2024https://conductscience.org/library/papers/38515565PubMed
38515178Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition.J Exp Clin Cancer Res2024https://conductscience.org/library/papers/38515178PubMed
38232457Thioredoxin (Trx): A redox target and modulator of cellular senescence and aging-related diseases.Redox Biol2024https://conductscience.org/library/papers/38232457PubMed

Download CSV of cited by

Genes12

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36978917

GET https://conductscience.org/api/papers/v1/36978917/references?page=2